Enlivex Therapeutics Ltd. (TLV:ENLV)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
355.80
+18.30 (5.42%)
Apr 27, 2025, 3:49 PM IDT
-34.82%
Market Cap 84.36M
Revenue (ttm) n/a
Net Income (ttm) -54.69M
Shares Out n/a
EPS (ttm) -2.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,181
Average Volume 21,909
Open 337.50
Previous Close 337.50
Day's Range 337.50 - 370.00
52-Week Range 316.60 - 650.00
Beta 0.85
RSI 42.40
Earnings Date Jun 13, 2025

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Oren Hershkovitz
Country Israel
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol ENLV
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.